<DOC>
	<DOCNO>NCT02870244</DOCNO>
	<brief_summary>Phase I clinical trial determine Phase II dose autologous TIL 1383I TCR gene modify T Cells use retrovirus . This novel National Cancer Institute ( NCI ) fund investigator initiated therapy patient advance melanoma .</brief_summary>
	<brief_title>Adoptive T Cell Immunotherapy Advanced Melanoma Using Engineered Lymphocytes</brief_title>
	<detailed_description>This Phase 1 dose escalation study design find high dose TIL 1383I TCR transduce T cell safely give . Three cohort 3 patient treat increase dos TIL 1383I TCR transduce T cell . Patients monitor clinically immunologically year infusion . Subjects Cohort 1 receive 7.5 X 10^6/kg TIL 1383I TCR transduce T cell . Subjects Cohort 2 receive 2.5 x 10^7/kg TIL 1383I TCR transduce T cell . Subjects Cohort 3 receive 7.5 x 10^7/kg TIL 1383I TCR transduce T cell .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients must diagnosis metastatic melanoma evaluable either clinically radiologically . Patients must 18 year age old . Patients must consent study must sign date approved consent form , conform federal institutional guideline . Patients must performance status ( PS ) 0 1 ECOG PS scale . Patients must ability provide write informed consent prior study specific screening procedure , understand patient right withdraw study time . Patients melanoma must positive tyrosinase HLAA2 pathologic review FNA , core excisional biopsy lesion . Cardiac ejection fraction great 50 percent determine screen echocardiogram . Patients undergone treatment antiCTLA4 , Cytotoxic TLymphocyte Antigen 4 , antibody must least 6 week last dose CTLA4 antibody evidence tumor progression enrol study . Patients undergone treatment antiPD1 , Programmed Death Receptor 1 , Blockade antiPDL1 antibody must least 4 week last dose antibody evidence tumor progression treat study . Patients V600E mutation eligible fail approved BRAF inhibitor MEK inhibitor therapy refuse treatment approve BRAF inhibitor MEK inhibitor . Patients treat prior Interleukin2 ( IL2 ) eligible . Sufficient cardiopulmonary reserve IL2 per institutional guideline . Special class subject fetus , pregnant woman , child , prisoner , institutionalized individual , others likely vulnerable . ECOG performance status 2 great . Patients history metastatic melanoma involve brain exclude active disease active disease within prior three month control surgery radiotherapy . Patients take steroids disease control pain management Patients must pregnant nursing potentially harmful effect agent develop fetus . Women men reproductive potential must agree use effective contraceptive method . Patients whose BRAF V600 mutation status unknown undergo attempt determine information , patient BRAF V600 mutation respond BRAF without MEK inhibitor therapy , BRAF V600 mutation offer option receive BRAF without MEK inhibitor therapy treatment melanoma exclude . No prior malignancy allow except follow adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree two year . Patients undergone immunotherapy target tyrosinase . Patients undergone immunotherapy combination nonmyeloablative chemotherapy . Any following abnormal laboratory value Absolute neutrophil count le 1.5 x 10^9/L Platelet count le 100 x 10^9/L Serum bilirubin great 1.5 x upper limit normal ULN Serum ALT , AST great 2.5 x ULN Serum ALP great 2 x ULN Serum Albumin le 2.5 g dL International Normalized Ratio , INR great 1.5 Serum creatinine calculate creatinine clearance method Cockcroft Gault , less 50mL min . Patients evidence active uncontrolled infection require treatment antibiotic . Any severe poorly control systemic disease , example hypertension , clinically significant cardiovascular , pulmonary , metabolic disease , disorder woundhealing , ulcer bone fracture . Patients receive chemotherapy investigational treatment within 4 week study start . Known infection HIV , HBV , HCV . Known hypersensitivity component study drug . Patients assess investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Adoptive T-Cell Transfer</keyword>
	<keyword>IL-2</keyword>
</DOC>